Trial Profile

A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KC 1036 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors KONRUNS Pharmaceutical

Most Recent Events

17 Oct 2024 Planned End Date changed from 31 Jul 2024 to 31 Dec 2025.
17 Oct 2024 Planned primary completion date changed from 31 Jul 2023 to 31 Oct 2025.
06 Jun 2023 Results (n=41; As of November 30, 2022) assessing the safety, tolerability, preliminary antitumor activity and pharmacokinetics of KC1036 in patients with advanced solid tumors, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com